{"id":"peginterferon-a-2a-plus-ribavirin","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-15","effect":"Hemolytic anemia"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression and mood changes"},{"rate":"20-30","effect":"Headache"},{"rate":"15-25","effect":"Insomnia"},{"rate":"20-30","effect":"Nausea"},{"rate":"5-10","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peginterferon alfa-2a is a long-acting interferon that binds to type I interferon receptors on immune cells and hepatocytes, triggering antiviral and immunomodulatory responses including upregulation of 2',5'-oligoadenylate synthetase and protein kinase R. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and depletes guanosine pools, reducing HCV replication. The combination provides synergistic antiviral activity against hepatitis C virus.","oneSentence":"Peginterferon alfa-2a activates interferon-alpha receptors to enhance antiviral immunity, while ribavirin inhibits viral RNA synthesis, together suppressing hepatitis C virus replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:42.012Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotypes 1-6)"}]},"trialDetails":[{"nctId":"NCT00215839","phase":"PHASE3","title":"HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy","status":"UNKNOWN","sponsor":"Hepatitis Resource Network","startDate":"","conditions":"Chronic Hepatitis C Infection in HIV Infected Persons, HIV Infections","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Peginterferon a-2a plus Ribavirin","genericName":"Peginterferon a-2a plus Ribavirin","companyName":"Hepatitis Resource Network","companyId":"hepatitis-resource-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peginterferon alfa-2a activates interferon-alpha receptors to enhance antiviral immunity, while ribavirin inhibits viral RNA synthesis, together suppressing hepatitis C virus replication. Used for Chronic hepatitis C virus infection (genotypes 1-6).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}